An interview with Neil Vargesson.

IF 4 2区生物学 Q1 DEVELOPMENTAL BIOLOGY

Development Pub Date : 2026-10-15 Epub Date: 2026-10-19 DOI:10.1242/dev.206180

引用次数: 0

Abstract

Neil Vargesson is Professor of Developmental Biology at the University of Aberdeen, with particular expertise in angiogenesis during embryonic development and the impact of pharmaceutical drugs, such as thalidomide, that cause limb and embryonic differences. His advocacy, communication and advisory work around thalidomide embryopathy, Primodos and drug safety has supported affected patients and their families across the globe, as well as influencing government health policies worldwide. A Fellow of the Royal Society of Edinburgh since 2021, Neil is the recipient of the 2026 British Society for Developmental Biology Wolpert Medal, which is awarded in honour of the late Lewis Wolpert for extraordinary contributions to the communication and teaching of developmental biology in the UK. Published to coincide with Lewis's birthday on 19 October, the following interview is a conversation with Neil about what the Wolpert Medal means to him as Lewis's last PhD student, his ethos and advice for doing science communication, as well as his outlook on the future of drug safety.

查看原文本刊更多论文

尼尔·瓦格森的采访。

尼尔·瓦格森（Neil Vargesson）是阿伯丁大学（University of Aberdeen）的发育生物学教授，他在胚胎发育过程中的血管生成和药物（如沙利度胺）的影响方面有着特别的专长，这些药物会导致肢体和胚胎的差异。他在沙利度胺胚胎病、Primodos和药物安全方面的宣传、沟通和咨询工作为全球受影响的患者及其家属提供了支持，并影响了全球政府的卫生政策。自2021年起成为爱丁堡皇家学会会员，尼尔是2026年英国发育生物学学会沃尔珀特奖章的获得者，该奖章是为了纪念已故的刘易斯沃尔珀特在英国发育生物学的交流和教学方面的杰出贡献而颁发的。10月19日恰逢刘易斯的生日，下面的采访是对尼尔的一次谈话，关于沃尔珀特奖章对他来说意味着什么，作为刘易斯的最后一个博士生，他的精神和对科学传播的建议，以及他对未来药物安全的看法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Development 生物-发育生物学

CiteScore

6.70

自引率

4.30%

发文量

433

审稿时长

3 months

期刊介绍： Development’s scope covers all aspects of plant and animal development, including stem cell biology and regeneration. The single most important criterion for acceptance in Development is scientific excellence. Research papers (articles and reports) should therefore pose and test a significant hypothesis or address a significant question, and should provide novel perspectives that advance our understanding of development. We also encourage submission of papers that use computational methods or mathematical models to obtain significant new insights into developmental biology topics. Manuscripts that are descriptive in nature will be considered only when they lay important groundwork for a field and/or provide novel resources for understanding developmental processes of broad interest to the community. Development includes a Techniques and Resources section for the publication of new methods, datasets, and other types of resources. Papers describing new techniques should include a proof-of-principle demonstration that the technique is valuable to the developmental biology community; they need not include in-depth follow-up analysis. The technique must be described in sufficient detail to be easily replicated by other investigators. Development will also consider protocol-type papers of exceptional interest to the community. We welcome submission of Resource papers, for example those reporting new databases, systems-level datasets, or genetic resources of major value to the developmental biology community. For all papers, the data or resource described must be made available to the community with minimal restrictions upon publication. To aid navigability, Development has dedicated sections of the journal to stem cells & regeneration and to human development. The criteria for acceptance into these sections is identical to those outlined above. Authors and editors are encouraged to nominate appropriate manuscripts for inclusion in one of these sections.